Kala Pharmaceuticals Inc (KALA) Expected to Announce Earnings of -$0.75 Per Share

Equities research analysts expect Kala Pharmaceuticals Inc (NASDAQ:KALA) to post earnings per share of ($0.75) for the current quarter, according to Zacks. Four analysts have made estimates for Kala Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.78) and the highest estimate coming in at ($0.73). Kala Pharmaceuticals reported earnings per share of ($0.46) in the same quarter last year, which indicates a negative year over year growth rate of 63%. The company is expected to issue its next quarterly earnings results on Thursday, May 9th.

On average, analysts expect that Kala Pharmaceuticals will report full year earnings of ($2.83) per share for the current fiscal year, with EPS estimates ranging from ($3.17) to ($2.44). For the next financial year, analysts anticipate that the business will report earnings of ($2.06) per share, with EPS estimates ranging from ($2.81) to ($1.37). Zacks’ EPS averages are an average based on a survey of research analysts that cover Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA) last announced its quarterly earnings data on Monday, March 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.23).

A number of research analysts have recently issued reports on the company. Jefferies Financial Group assumed coverage on Kala Pharmaceuticals in a research note on Thursday, March 14th. They issued a “buy” rating and a $15.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Kala Pharmaceuticals in a research note on Thursday, December 27th. Zacks Investment Research downgraded Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 22nd. BidaskClub raised Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, February 20th. Finally, Wedbush set a $51.00 price objective on Kala Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, January 16th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $20.58.

A number of hedge funds have recently bought and sold shares of KALA. American International Group Inc. raised its stake in Kala Pharmaceuticals by 34.3% during the 4th quarter. American International Group Inc. now owns 10,369 shares of the company’s stock worth $51,000 after buying an additional 2,646 shares during the period. Rhumbline Advisers acquired a new position in Kala Pharmaceuticals during the 4th quarter worth approximately $75,000. Bradley Foster & Sargent Inc. CT acquired a new position in Kala Pharmaceuticals during the 4th quarter worth approximately $115,000. United Services Automobile Association raised its stake in Kala Pharmaceuticals by 33.6% during the 4th quarter. United Services Automobile Association now owns 24,218 shares of the company’s stock worth $118,000 after buying an additional 6,088 shares during the period. Finally, Squarepoint Ops LLC raised its stake in Kala Pharmaceuticals by 12.4% during the 4th quarter. Squarepoint Ops LLC now owns 27,871 shares of the company’s stock worth $136,000 after buying an additional 3,071 shares during the period. 67.20% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:KALA opened at $8.02 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 10.41 and a quick ratio of 10.17. Kala Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $17.53.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Recommended Story: What Are Cryptocurrencies?

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit